BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio
Published . Updated .
Key takeaways
- BioCryst Pharmaceuticals (NASDAQ:BCRX) expects revenue to land at the upper end of its $625 million to $645 million guidance range this year, CEO Charlie Gayer said at a Jefferies conference, while outlining plans to expand its hereditary angioedema portfolio and add
- Exposed: BCRX, JEF, LLY, JNJ, PFE
- Market reaction: price tracking starts with the next trading session.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest and never sell or share it. See our privacy policy.
BioCryst Pharmaceuticals (NASDAQ:BCRX) expects revenue to land at the upper end of its $625 million to $645 million guidance range this year, CEO Charlie Gayer said at a Jefferies conference, while outlining plans to expand its hereditary angioedema portfolio and add
Directly affected
- BCRX Biocryst Pharmaceuticals-6.2% 18d
Named in this report.
- JEF Jefferies Financial Group+3.0% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- PFE Pfizer+5.2% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- MRK Merck+3.5% 30d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| BCRX | +4.11% | +3.01% | base | after close | after close | after close | after close |
| JEF | +11.69% | +4.00% | base | after close | after close | after close | after close |
| XLV | +6.43% | +4.39% | base | after close | after close | after close | after close |
| XBI | +4.51% | +0.86% | base | after close | after close | after close | after close |
| LLY | +6.91% | +4.75% | base | after close | after close | after close | after close |
| JNJ | +7.01% | +4.30% | base | after close | after close | after close | after close |
| PFE | +4.82% | +3.23% | base | after close | after close | after close | after close |
| MRK | +11.32% | +8.02% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio Yahoo Finance
Source: Yahoo Finance
How far Select Sector Spdr Tr (XLV) has moved since 20 Nov 2026
| Company | When | Move | Status |
|---|---|---|---|
| BCRX | three days earlier | +3.01% | final price |
| BCRX | five days earlier | +4.11% | final price |
| JEF | three days earlier | +4.00% | final price |
| JEF | five days earlier | +11.69% | final price |
| Johnson & Johnson (JNJ) | three days earlier | +4.30% | final price |
| Johnson & Johnson (JNJ) | five days earlier | +7.01% | final price |
| Eli Lilly (LLY) | three days earlier | +4.75% | final price |
| Eli Lilly (LLY) | five days earlier | +6.91% | final price |
| Merck (MRK) | three days earlier | +8.02% | final price |
| Merck (MRK) | five days earlier | +11.32% | final price |
| Pfizer (PFE) | three days earlier | +3.23% | final price |
| Pfizer (PFE) | five days earlier | +4.82% | final price |
| Spdr Series Trust (XBI) | three days earlier | +0.86% | final price |
| Spdr Series Trust (XBI) | five days earlier | +4.51% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | +4.39% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | +6.43% | final price |
Congressional trades in the stocks in this story
- Rep. David J. Taylor sold Eli Lilly (LLY), worth $1,001 - $15,000 on 3 Nov 2026. That is 17 days before publication. Filed 12 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 31 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 77 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 44 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 51 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 77 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 57 days before publication. Filed 7 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies carried with this story
- XLV Select Sector Spdr Tr
Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 20 Nov 2026 story “BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio.” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
- XBI Spdr Series Trust
Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence in the 20 Nov 2026 story “BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio.” Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
- LLY Eli Lilly
Eli Lilly (LLY) is linked, with no stored direction, medium confidence in the 20 Nov 2026 story “BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio.” Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- JNJ Johnson & Johnson
Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence in the 20 Nov 2026 story “BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio.” Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- PFE Pfizer
Pfizer (PFE) is linked, with no stored direction, medium confidence in the 20 Nov 2026 story “BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio.” Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- MRK Merck
In “BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
On 20 Nov 2026, “BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio” is the story that connects Select Sector Spdr Tr (XLV) to this story.
For Select Sector Spdr Tr (XLV), the reason on file says Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
A second company, Spdr Series Trust (XBI), is listed for a different reason: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
Dates and price levels for Select Sector Spdr Tr (XLV)
LLY traded between 1239.21 and 1458.90 across 20 sessions. The latest close on file is 1430.09.
A simple score for Select Sector Spdr Tr (XLV)
46 out of 100
“BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio” scores 46 out of 100. The score uses 1 source, and 6 linked companies.